XML 23 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
Related Party Transactions (Details Textual) (USD $)
 0 Months Ended 1 Months Ended 6 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 6 Months Ended 12 Months Ended 6 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 6 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended
May 20, 2014
Apr. 30, 2012
Jun. 30, 2014
Dec. 31, 2013
Dec. 31, 2012
Jul. 18, 2014
Subsequent Event [Member]
Apr. 30, 2012
Series A Preferred Stock [Member]
Dec. 31, 2013
Series A Preferred Stock [Member]
Jun. 30, 2014
Common Stock [Member]
Dec. 31, 2013
Common Stock [Member]
Dec. 31, 2012
Common Stock [Member]
Jun. 30, 2014
Medeor [Member]
May 19, 2014
Placement Agent [Member]
Drugs
Dec. 06, 2011
Placement Agent [Member]
Oct. 24, 2013
Placement Agent [Member]
Jun. 30, 2014
Placement Agent [Member]
Dec. 31, 2013
Placement Agent [Member]
Dec. 31, 2012
Placement Agent [Member]
Dec. 06, 2011
Advisory Firm [Member]
Dec. 31, 2013
Advisory Firm [Member]
Class of Warrant or Right [Line Items]                                        
Advisory services fees     $ 12,500                         $ 25,000   $ 272,000 $ 12,500  
Percent of fully vested warrants to purchase common stock                               5.00%     12.00%  
Exercise price per share                               $ 1.50     $ 0.01  
Issuance of warrants to purchase common stock                               4,290,950        
Issuance of warrants to purchase common stock description                               The Placement Agent shall also be entitled to the compensation set forth above as well for any cash exercise of Warrants within six (6) months of the final closing of the Offering as well as a five percent (5%) solicitation fee for any Warrants exercised as a result of any redemption of any Warrants. If the Company elects to call the warrants, the Placement Agent shall receive a warrant solicitation fee equal to 5% of the funds solicited by the Placement Agent upon exercise of the warrants.        
Term of warrants                               5 years        
Maximum reimbursement expenses, monthly                                       5,000
Proceeds from sale of Series A preferred stock        3,494,428 3,220,018                     3,089,500 554,700 470,300    
Issuance of common stock to founder for cash 2,000,000                                      
Issuance of common stock for services, Shares           250,000 1,725,000 1,275,156 29,052 56,394 68,356                  
Issuance of common stock to acquire Medeor, Inc. at fair value, Shares   17,089               2,500,000                    
Research and development expense       3,750,000                                
Proceeds from issuance of subordinated promissory notes                                 68,400 25,100    
Related party transaction, Description of Transaction                           In consideration for its services, the placement agent received: (a re-activation fee of $15,000, (b) a cash fee equal to 7% of the Notes Conversion and 10% of the gross proceeds raised in the Financings, and (c) non-accountable expense reimbursement equal to 2% of the gross proceeds raised. The placement agent or its designees also received warrants to purchase shares of the Company's common stock in an amount equal to 10% of the shares of common stock and warrants issued or issuable as part of the units sold in the Series A Preferred Stock Offering and Notes Offerings. In consideration for its services, the Placement Agent was eligible to receive: (a) a cash success fee equal to 8% of the value of the transaction plus a 2% non-reimbursable expense fee which was subsequently modified to a maximum of $150,000 plus, (b) $50,000 for a Fairness Opinion fee deductible against the success fee, and (c) a $50,000 activation fee.          
Offering price description                         (a) a cash commission in the amount of ten percent (10%) of the gross proceeds of the Offering received from investors at a Closing as well as a non-accountable expense reimbursement equal to two percent (b) (2%) of the gross proceeds of the Offering received from investors at a Closing and an activation fee of $25,000.              
Number of agreements                         2              
Activation fee                         $ 25,000              
Business acquisition, Description                           8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the services. 8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the services.          
Royalty payments description                      
(A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product.
                
Royalty received by licensee description                      
 (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively.